Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) FCF Margin (2016 - 2026)

Intellia Therapeutics has reported FCF Margin over the past 12 years, most recently at 780.34% for Q1 2026.

  • Quarterly FCF Margin rose 11587.0% to 780.34% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 549.51% through Mar 2026, up 27408.0% year-over-year, with the annual reading at 583.36% for FY2025, 2043.0% up from the prior year.
  • FCF Margin was 780.34% for Q1 2026 at Intellia Therapeutics, down from 301.16% in the prior quarter.
  • Over five years, FCF Margin peaked at 4852.74% in Q4 2023 and troughed at 976.87% in Q3 2024.
  • The 5-year median for FCF Margin is 696.07% (2023), against an average of 369.56%.
  • Year-over-year, FCF Margin skyrocketed 2256279bps in 2022 and then plummeted -548172bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 690.94% in 2022, then soared by 802bps to 4852.74% in 2023, then crashed by -113bps to 628.98% in 2024, then soared by 52bps to 301.16% in 2025, then plummeted by -159bps to 780.34% in 2026.
  • Per Business Quant, the three most recent readings for NTLA's FCF Margin are 780.34% (Q1 2026), 301.16% (Q4 2025), and 557.97% (Q3 2025).